This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| gastric inhibitory polypeptide | |
|---|---|
| Name | Gastric inhibitory polypeptide |
| Other names | Glucose-dependent insulinotropic polypeptide |
| Precursor | ProGIP |
| Gene | GIP |
| Tissue | Pancreas, Duodenum, Jejunum |
| Function | Incretin hormone, stimulates Insulin secretion |
| Receptor | GIP receptor |
gastric inhibitory polypeptide is a peptide hormone produced in the upper Small intestine that modulates postprandial nutrient handling and endocrine responses. Historically identified in gastrointestinal physiology studies linked to Claude Bernard-era concepts, it gained clinical prominence with discoveries involving Frederick Banting-era insulin research and later work in incretin biology by researchers connected to Novo Nordisk and Eli Lilly and Company. Major contributions to understanding its role have emerged from laboratories at institutions such as Harvard University, University of Oxford, Massachusetts Institute of Technology, Stanford University, and Karolinska Institutet.
Gastric inhibitory polypeptide (GIP) was originally characterized in classical secretion studies and later redefined as an incretin implicated in glucose homeostasis, linking findings from investigators at Johns Hopkins University, University of Cambridge, and Yale University. The peptide connects clinical frameworks involving Type 2 diabetes mellitus, pharmacology programs at GlaxoSmithKline and AstraZeneca, and endocrine research networks including American Diabetes Association symposia and European Association for the Study of Diabetes congresses. Its clinical narrative intersects with drug development pipelines at Pfizer, Sanofi, and academic consortia such as NIH-funded research centers.
GIP is synthesized as a prohormone encoded by the GIP gene located in human genomic maps curated by National Center for Biotechnology Information and characterized with techniques developed at Cold Spring Harbor Laboratory and EMBL. Structural elucidation employed mass spectrometry methods pioneered at Max Planck Institute for Biochemistry and crystallography approaches from Rutherford Appleton Laboratory and European Synchrotron Radiation Facility. Biosynthesis in enteroendocrine K cells was defined using cell line models from University of California, San Francisco and primary tissue preparations from studies affiliated with Mayo Clinic. Processing enzymes implicated include prohormone convertases first described by teams at Rockefeller University and peptide degradation pathways explored by researchers at Imperial College London.
GIP exerts incretin effects on pancreatic beta cells, a relationship central to findings in clinical trials at Cleveland Clinic and population studies from Framingham Heart Study. Beyond insulinotropic actions, roles in lipid metabolism and adipocyte biology were investigated in research centers such as Cold Spring Harbor Laboratory and Salk Institute for Biological Studies, with translational implications discussed at World Health Organization workshops. Neuroendocrine interactions involving hypothalamic circuits were mapped in laboratories at Columbia University and University of Pennsylvania, linking to appetite studies led by teams at Yale University and University College London.
Secretion dynamics of GIP are regulated by nutrient stimuli characterized in feeding studies at Johns Hopkins University School of Medicine and tracer experiments from National Institutes of Health programs. Enteroendocrine signaling networks were probed using tools developed at Broad Institute and Wellcome Trust Sanger Institute. Regulation by enzymes such as dipeptidyl peptidase-4 was clarified alongside therapeutic strategies from Merck & Co. and academic collaborators at University of Copenhagen. Comparative secretion profiles in bariatric surgery cohorts were reported from clinical centers including Cleveland Clinic, Mount Sinai Health System, and Mayo Clinic.
GIP’s incretin properties interface with diabetes therapeutics developed by companies like Novo Nordisk and Eli Lilly and Company and were central to investigations at University of Oxford and Imperial College London. Dual agonists targeting GIP and GLP-1 receptors emerged from translational programs at Roche and academic spinouts linked to MIT and Stanford University. Clinical trials coordinated through networks such as FDA-regulated multicenter consortia and European Medicines Agency submissions evaluated safety and efficacy in Type 2 diabetes mellitus and obesity, with outcome reports presented at American Diabetes Association and European Association for the Study of Diabetes meetings. Endocrine disorders and metabolic syndrome cohorts studied at Johns Hopkins Hospital and Beth Israel Deaconess Medical Center informed risk–benefit assessments guiding regulatory decisions at FDA and market authorizations managed by Medicines and Healthcare products Regulatory Agency.
GIP signals via its G protein–coupled receptor activating cAMP pathways characterized in biochemical studies at University of California, Berkeley and University of Michigan. Downstream effectors and cross-talk with insulin receptor signaling were dissected in molecular labs at Rockefeller University and Massachusetts General Hospital. Pharmacodynamic modeling applied by teams at Regeneron Pharmaceuticals and Bayer AG integrated receptor pharmacology with metabolic endpoints measured in cohorts from Framingham Heart Study and longitudinal studies at Harvard Medical School. Signal transduction modules intersect with pathways cataloged by KEGG and mechanistic annotations curated by UniProt.
Comparative sequence analyses across vertebrates utilized resources from Ensembl and evolutionary frameworks developed by researchers at University of California, Santa Cruz and Smithsonian Institution. Studies in model organisms such as Mus musculus and Rattus norvegicus informed functional conservation, while investigations in non-mammalian species were conducted by groups at Max Planck Institute for Evolutionary Anthropology and University of Tokyo. Phylogenetic mapping integrated datasets from GenBank and analytical tools originating from Broad Institute and European Bioinformatics Institute.
Category:Hormones